AdvisorShares Investments LLC Sells 10,941 Shares of Supernus Pharmaceuticals, Inc. $SUPN

AdvisorShares Investments LLC reduced its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 38.5% during the first quarter, Holdings Channel reports. The institutional investor owned 17,453 shares of the specialty pharmaceutical company’s stock after selling 10,941 shares during the period. AdvisorShares Investments LLC’s holdings in Supernus Pharmaceuticals were worth $902,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Rubric Capital Management LP acquired a new position in Supernus Pharmaceuticals during the 2nd quarter valued at about $21,908,000. Assenagon Asset Management S.A. bought a new position in shares of Supernus Pharmaceuticals during the 1st quarter worth approximately $27,428,000. Woodline Partners LP lifted its position in shares of Supernus Pharmaceuticals by 63.5% during the 3rd quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock worth $60,398,000 after buying an additional 490,835 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of Supernus Pharmaceuticals by 2,847.0% in the 1st quarter. SG Americas Securities LLC now owns 377,213 shares of the specialty pharmaceutical company’s stock worth $19,498,000 after buying an additional 364,413 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Supernus Pharmaceuticals by 67.1% in the third quarter. Bank of America Corp DE now owns 842,890 shares of the specialty pharmaceutical company’s stock valued at $40,282,000 after acquiring an additional 338,584 shares in the last quarter.

Supernus Pharmaceuticals Stock Performance

SUPN stock opened at $48.05 on Friday. The company has a market capitalization of $2.79 billion, a price-to-earnings ratio of -94.22, a PEG ratio of 1.03 and a beta of 0.54. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $31.35 and a fifty-two week high of $59.68. The stock has a fifty day moving average of $47.18 and a 200-day moving average of $49.50.

Analyst Ratings Changes

A number of brokerages recently commented on SUPN. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, June 24th. Zacks Research raised Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Finally, Wall Street Zen upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $62.17.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.